The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.
Most B-cell-related disorders can be cured with conventional agents; however, relapse is common, creating a need for additional therapeutic options. In agreement, recent biomarker studies corroborate the role played by functional crosstalk between malignant B cells and microenvironment which have added texture to clinical outcome. Here we outline the essential role of the tumor-associated niche in B-cell Lymphoma/Leukemia pathogenesis, in an attempt to optimize the use of microenvironment-targeted drugs and anti-CD20 antibodies in the various subsets.
a Biotechnology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.
Vahideh
V
Ahmadzadeh
b Department of Biology , Tabriz University , Tabriz , Iran.
Roghaye
R
Tofigh
a Biotechnology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|c Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.
Safar
S
Farajnia
d Department of Cellular and Molecular Biology , Azarbaijan Shahid Madani University , Tabriz , Iran.
Nasser
N
Pouladi
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001402:B-Lymphocytes; D003131:Combined Modality Therapy; D004357:Drug Synergism; D006801:Humans; D007167:Immunotherapy; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D059016:Tumor Microenvironment
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20
B-cell malignancies; anti-CD20 antibodies; combination therapies; tumor microenvironment